CA-CEPTON-TECHNOLOGIES
1.3.2022 15:02:47 CET | Business Wire | Press release
Silicon Valley-based smart lidar solution provider Cepton, Inc. (Nasdaq: CPTN) (“Cepton”) and Fibre Based Integrations , an established fiber optics systems house, are working together to develop lidar-based vehicle detection solutions in Cape Town, South Africa, to enable smart transportation infrastructure city-wide.
This joint effort combines Fibre Based Integrations’ expertise in optics system integration and Cepton’s innovative lidar technologies to help the City of Cape Town monitor lane usage and identify vehicles using incorrect lanes. Fibre Based Integrations has deployed vehicle classification systems on traffic lights at intersections and overhead devices that utilize Cepton’s Helius® Smart Lidar System with Vista®-P lidar sensors .
Many of Cape Town’s roads have designated bus lanes to ensure the efficiency of public transportation, and Fibre Based Integrations’ lidar-enabled systems will allow the city technology department to gather highly accurate, real-time lane usage data to enable analytics that help identify ways to improve traffic flow and safety for motorists and pedestrians.
By utilizing lidar’s outstanding perception capabilities, the systems can provide useful information such as vehicle size, traffic volume, frequency, lane positioning and potential obstructions. Based on this information, system operators can gain valuable insight about how a specific intersection or piece of road is being used – including unauthorized vehicle types in designated bus lanes, peak traffic time windows, real-time lane occupancy status, wait time at traffic lights and accident-prone areas.
Josh Goosen, System Engineer at Fibre Based Integrations, said: “The reason we chose to deploy lidars in our vehicle detection and classification systems is their superior accuracy. We have previously tested radars and some other types of sensors, and we found that they lack the resolution needed to accurately locate and count vehicles and provide accurate 3D information about their sizes and speeds.
We found Cepton lidars to be the best performing and most accurate compared with others we tested, and this has unlocked new possibilities for implementing our smart city solutions with the City of Cape Town.”
Lidar technology has come to play an increasingly important role in the smart cities sector. It brings a higher level of accuracy and efficiency to existing sensor technologies to help the overall system eliminate detection errors. Lidars offer a much higher spatial resolution than radars, and perform better than cameras in various weather and lighting conditions to provide high-accuracy data 24/7. Lidars also help protect people’s privacy as they do not capture biometric information , making them suitable in venues where cameras might raise privacy concerns. The addition of lidars to smart city applications helps effectively reduce false negatives and false positives, while making systems more data efficient.
Cepton’s lidars use a patented imaging technology called Micro Motion Technology (MMT®) to help system integrators maximize the benefit of the lidar technology. The rotation-free, mirrorless and frictionless MMT design makes Cepton lidars reliable, rugged and compact, which in turn offers ease of integration and affordability for scalable applications.
In the solutions deployed by Fibre Based Integrations, Cepton’s Vista-P lidar sensors are interconnected through the Helius perception software, creating a network of smart lidar sensors to offer real-time detection, tracking and classification of vehicles and pedestrians. This enables extendable smart transportation infrastructure that collects and analyzes traffic data from different locations, while helping optimize its overall bandwidth allocation, as lidars output only a fragment of the data volume output from video camera-based alternatives.
Fibre Based Integrations and City of Cape Town are also exploring using Cepton’s lidars to augment the city’s analog and video systems with an additional layer of functionality and performance. The aim is to blend human and vehicle classification, enabled by lidar, with an AI platform to understand how both interact with the city environment. This will help collect useful information for traffic management and urban planning through machine learning, while minimizing disruption to people’s daily lives.
Klaus Wagner, Director of Product Management and Marketing at Cepton, added: “If our cities are to become smarter, then plug and play solutions like the ones we have created with Fibre Based Integrations must play a vital role in helping them do so.
Lidar has the ability to make people’s everyday lives easier even without them being fully aware of it, and that is what makes smart transport systems so intelligent. We look forward to continuing our work with Fibre Based Integrations in our effort to make Cape Town and other cities in South Africa safer. We also believe that by enabling a higher level of traffic efficiency, we can help cities build a greener environment.”
About Cepton, Inc.
Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. With its patented Micro Motion Technology (MMT®), Cepton aims to take lidar mainstream and achieve its vision of safe and autonomous transportation for everyone.
Cepton has been awarded the largest known ADAS lidar series production award in the industry to date, based on the number of vehicle models awarded, to support General Motors’ Ultra Cruise program. Cepton is also engaged with all other Top 10 global OEMs.
Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, CA and has a center of excellence facility in Troy, MI to provide local support to the OEM and Tier 1-studded Metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow Cepton on Twitter and LinkedIn .
About Fibre Based Integrations
Fibre Based Integrations is an established fibre optic systems house serving major project houses and end users in the Telecommunications, CCTV, Process and Datacomms industry.
Our success in attracting business from our customers is as a result of our commitment to supply a total turnkey solution and to maintain a general quality standard that permeates all aspects of the project, from documentation to all the components and the optical line terminating equipment used.
As a result of years of experience gained in the field of fibre installation and integration, our highly skilled installation staff is the foundation on which the company is built. To enable Fibre Based Integrations to work to the most exacting standards, the installation teams are backed by the latest state of the art fusion splicing machines, OTDR testing equipment and installation equipment. All commissioning activities are conducted to fully documented procedures, which form an intrinsic part of the final hand-over.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220301005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
